Keyphrases
Carboplatin
100%
Triple-negative Breast Cancer
100%
Penetrance
100%
Veliparib
100%
Peripheral Blood Mononuclear Cells
44%
PARP Inhibitor (PARPi)
44%
Tumor
33%
Adduct Formation
33%
Xenograft
22%
Inductively Coupled Plasma Mass Spectrometry
22%
Matrix-assisted Laser Desorption Ionization (MALDI)
22%
MDA-MB-231
22%
MDA-MB-436
22%
Tumor Penetration
22%
Mass Spectrometry Imaging
22%
Carrier Ratio
22%
HCC70
22%
Cell-based
11%
SCID Mice
11%
Tumor Cells
11%
High Dose
11%
Phase 1 Study
11%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
11%
Cell Population
11%
Blood Samples
11%
DNA Damage
11%
Spatial Heterogeneity
11%
Talazoparib
11%
Highly Heterogeneous
11%
Drug Exposure
11%
DNA Binding
11%
Pearson Correlation
11%
Pharmacokinetic Modeling
11%
Core Needle Biopsy
11%
Tissue Penetration
11%
Nuclear DNA (nDNA)
11%
Xenograft Tumor
11%
Non-carriers
11%
Mouse Xenograft
11%
Triple-negative Breast Cancer Cells
11%
Non-response
11%
Fresh-frozen
11%
Model Correlation
11%
Drug Penetration
11%
Embedded Cores
11%
Formation Heterogeneity
11%
Concentration Value
11%
Human Triple Negative Breast Cancer
11%
Patient Blood Samples
11%
Medicine and Dentistry
Breast Tumor
100%
Carboplatin
100%
Penetrance
100%
Veliparib
100%
PARP Inhibitor
44%
Peripheral Blood Mononuclear Cell
44%
Neoplasm
33%
Triple Negative Breast Cancer
33%
Xenograft
33%
Matrix-Assisted Laser Desorption-Ionization
22%
Tumor
22%
Inductively Coupled Plasma Mass Spectrometry
22%
Low Drug Dose
11%
Cancer Cell
11%
Drug Megadose
11%
Pharmacokinetics
11%
Cell Population
11%
DNA Binding
11%
Plasmacytoma
11%
Needle Biopsy
11%
Tumor Xenograft
11%
Optical Coherence Tomography
11%
Drug Exposure
11%
Liquid Chromatography-Mass Spectrometry
11%
Cell Nucleus DNA
11%
Drug Penetration
11%
Talazoparib
11%
SCID Mouse
11%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Tumor
100%
Veliparib
100%
Carboplatin
100%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
44%
Triple Negative Breast Cancer
33%
Neoplasm
33%
Inductively Coupled Plasma
22%
Matrix-Assisted Laser Desorption/Ionization
22%
Pharmacokinetic Modeling
11%
SCID Beige Mouse
11%
Talazoparib
11%
Cell Nucleus DNA
11%
Plasmacytoma
11%